New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
14:08 EDTVVUSVIVUS Qsymia Q4 patients beter but revenues below Street, says Credit Suisse
Credit Suisse said Qsymia Q4 prescription numbers are better than expected but revenues are likely to come in below consensus. The firm rates shares an Outperform with a $16 price target.
News For VVUS From The Last 14 Days
Check below for free stories on VVUS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 11, 2014
12:42 EDTVVUSOrexigen falls after FDA requires warnings on Contrave label
Subscribe for More Information
10:59 EDTVVUSArena competition picks up after Contrave approval, says Piper Jaffray
Subscribe for More Information
08:01 EDTVVUSOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
September 9, 2014
12:46 EDTVVUSNovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use